![novo_flag](https://pharmafile.com/wp-content/uploads/2016/06/novo_flag_4-1024x1016.jpg)
Novo Nordisk says Victoza lowers risk of heart attacks in diabetes patients
pharmafile | June 14, 2016 | News story | Manufacturing and Production, Research and Development | Novo Nordisk, Victoza, drug trial, type 2 diabetes
Danish diabetes drugmaker giant Novo Nordisk (NYSE: NVO) on Tuesday said a large study showed its Victoza (liraglutide) reduced the risk of heart attack in combination with standard therapy for type 2 diabetes patients.
Mads Krogsgaard Thomsen, chief science officer of Novo Nordisk, said: “We are very excited by the Leader trial results that demonstrate a significant reduction in major cardiovascular events among type 2 diabetes patients treated with Victoza, including all-cause death. For us, this marks the beginning of a new era where our R&D focus will go beyond glucose control.”
Victoza is the only approved GLP-1 receptor agonist to demonstrate a superior reduction of major CV events vs placebo, both on top of standard of care, in a cardiovascular outcomes trial.
John Buse, chairman of the trial steering committee, said: “These findings are exciting, as it demonstrates that Victoza can improve outcomes beyond glucose reduction and weight loss by helping to avoid cardiovascular complications and death in people with type 2 diabetes.
“Type 2 diabetes treatments that can also reduce cardiovascular risk are important since cardiovascular disease is the leading cause of death worldwide in this patient population,” he added.
Anjali Shukla
Related Content
![](https://pharmafile.com/wp-content/uploads/2023/04/towfiqu-barbhuiya-zjak9jqxeda-unsplash_1_0-300x200.jpg)
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
![](https://pharmafile.com/wp-content/uploads/2023/12/shutterstock_2169082807-300x200.jpg)
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …
![](https://pharmafile.com/wp-content/uploads/2023/05/mufid-majnun-cm1au42fnrg-2-300x200.jpg)
Novo Nordisk shares positive results from COMBINE 3 phase 3a trial
Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly …